Possibilities of treatment of patients with physiological and functional pulmonary deficiency symptoms after previous COVID-19 infection (review of the symposium with international participation at the XXXI National Congress on Respiratory Diseases)


DOI: https://dx.doi.org/10.18565/therapy.2021.10.138-146

Mubarakshina O.A.

N.N. Burdenko Voronezh State Medical University of the Ministry of Healthcare of Russia
Abstract. The article contains an overview of key points from reports on topical issues of therapy and rehabilitation of COVID-19 patients, presented by experts at one of the symposia of the XXXI National Congress on Respiratory Diseases (October 2021, Moscow). Particular attention is paid to modern data concerning the role of hyaluronic acid of COVID-19 pathogenesis, development and maintenance of the inflammatory process, formation of pathological respiratory discharge with specific physicochemical properties, as well as in postcovid residual changes in lung tissue. Examples of the use of bovhyaluronidase azoximer (Longidaza) medicine in the treatment and rehabilitation of patients with COVID-19 in real clinical practice are given.
Keywords: bovhyaluronidase azoxymer, post-COVID-19 syndrome, novel coronavirus infection COVID-19, hyaluronic acid
Read entire article

Literature


  1. Hallgren R., Samuelsson T., Laurent T.C., Modig J. Accumulation of hyaluronan (hyaluronic acid) in the lung in adult respiratory distress syndrome. Am Rev Respir Dis. 1989; 139(3): 682–87. doi: 10.1164/ajrccm/139.3.682.

  2. Hellman U., Karlsson M.G., Engstrom-Laurent A. et al. Presence of hyaluronan in lung alveoli in severe Covid-19: An opening for new treatment options? J Biol Chem. 2020; 295(45): 15418–22. doi: 10.1074/jbc.AC120.015967.

  3. Labrou N. Therapeutic enzymes: Function and clinical implications. Advances in Experimental Medicine and Biology, 1148. Springer, Singapore. 2019; 386 pp. doi: 10.1007/978-981-13-7709-9. ISBN: 978-981-13-7708-2.

  4. Garantziotis S., Brezina M., Castelnuovo P., Drago L. The role of hyaluronan in the pathobiology and treatment of respiratory disease. Am J Physiol Lung Cell Mol Physiol. 2016; 310(9): L785–95. doi: 10.1152/ajplung.00168.2015.

  5. Kaber G., Kratochvil M.J., Burgener E.B. et al. Hyaluronan is abundant in COVID-19 respiratory secretions. medRxiv. 2020: 2020.09.11.20191692. doi: 10.1101/2020.09.11.20191692. Preprint.

  6. Esposito A.J., Bhatraju P.K., Stapleton R.D. et al. Hyaluronic acid is associated with organ dysfunction in acute respiratory distress syndrome. Crit Care. 2017; 21(1): 304. doi: 10.1186/s13054-017-1895-7.

  7. Osmanov I.M., Spiridonova E., Bobkova P. et al.; Sechenov StopCOVID Research Team. Risk factors for long covid in previously hospitalised children using the ISARIC Global follow-up protocol: A prospective cohort study. Eur Respir J. 2021: 2101341. doi: 10.1183/13993003.01341-2021.

  8. Solomon J.J., Heyman B., Ko J.P. et al. CT of post-acute lung complications of COVID-19. Radiology. 2021; 301(2): E383–E395. doi: 10.1148/radiol.2021211396.


About the Autors

Olga A. Mubarakshina, PhD, associate professor of the Department of clinical pharmacology, N.N. Burdenko Voronezh State Medical University of the Ministry of Healthcare of Russia. Address: 394024, Voronezh, 2 Zdorov`ya Lane. Tel.: +7 (473) 237-10-11. E-mail: mubarakshina@mail.ru


Similar Articles

Back to Content

Бионика Медиа